The Latest Analyst Ratings for Karuna Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 8 Wall Street analysts have provided ratings for Karuna Therapeutics (NASDAQ:KRTX), with an average price target of $275.5, which is higher than the current price of $179.73. All 8 analysts are bullish or somewhat bullish, with no indifferent, somewhat bearish, or bearish ratings. The current average price target has decreased by 1.69% from the previous target of $280.25.
November 20, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have a bullish outlook on Karuna Therapeutics with a consensus price target of $275.5, indicating a potential upside from the current price of $179.73.
The unanimous bullish sentiment from analysts, coupled with a price target significantly above the current stock price, suggests a positive short-term impact on KRTX's stock price. However, the slight decrease in the average price target may temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100